Copeland Capital Management LLC Trims Position in Cencora, Inc. $COR

Copeland Capital Management LLC trimmed its position in Cencora, Inc. (NYSE:COR) by 4.8% during the 3rd quarter, HoldingsChannel reports. The firm owned 52,742 shares of the company’s stock after selling 2,635 shares during the period. Copeland Capital Management LLC’s holdings in Cencora were worth $16,484,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the company. Norges Bank bought a new position in shares of Cencora in the 2nd quarter worth approximately $695,215,000. Artisan Partners Limited Partnership purchased a new stake in Cencora during the second quarter valued at approximately $411,888,000. Vanguard Group Inc. boosted its stake in shares of Cencora by 5.3% during the 2nd quarter. Vanguard Group Inc. now owns 22,479,041 shares of the company’s stock worth $6,740,340,000 after acquiring an additional 1,125,661 shares during the last quarter. Viking Global Investors LP grew its position in shares of Cencora by 95.0% during the 2nd quarter. Viking Global Investors LP now owns 2,081,732 shares of the company’s stock valued at $624,207,000 after acquiring an additional 1,013,913 shares during the period. Finally, Ameriprise Financial Inc. grew its position in shares of Cencora by 228.6% during the 2nd quarter. Ameriprise Financial Inc. now owns 974,505 shares of the company’s stock valued at $292,207,000 after acquiring an additional 677,952 shares during the period. 97.52% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total transaction of $1,146,377.10. Following the completion of the transaction, the executive vice president owned 23,891 shares of the company’s stock, valued at $8,173,111.10. This represents a 12.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Silvana Battaglia sold 1,677 shares of Cencora stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the sale, the executive vice president directly owned 18,796 shares in the company, valued at $6,484,620. This trade represents a 8.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 20,317 shares of company stock worth $7,009,260 in the last 90 days. 10.80% of the stock is currently owned by corporate insiders.

Cencora Stock Down 0.3%

Shares of COR opened at $340.08 on Tuesday. The business’s 50 day moving average is $348.91 and its 200 day moving average is $315.59. The company has a current ratio of 0.90, a quick ratio of 0.55 and a debt-to-equity ratio of 4.32. Cencora, Inc. has a 12-month low of $223.92 and a 12-month high of $377.54. The company has a market capitalization of $65.97 billion, a PE ratio of 42.78, a price-to-earnings-growth ratio of 1.62 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion during the quarter, compared to the consensus estimate of $83.36 billion. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm’s revenue for the quarter was up 5.9% compared to the same quarter last year. During the same period in the prior year, the company posted $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. Research analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. The ex-dividend date was Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. This is an increase from Cencora’s previous quarterly dividend of $0.55. Cencora’s payout ratio is presently 30.19%.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on COR shares. JPMorgan Chase & Co. raised their target price on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a report on Tuesday, November 11th. Wells Fargo & Company raised their price objective on Cencora from $354.00 to $405.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Mizuho lifted their price objective on Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday, November 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a report on Monday, December 22nd. Finally, Robert W. Baird set a $392.00 target price on shares of Cencora in a research note on Tuesday, December 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $373.25.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.